neuroimaging-biomarkers

Migration, Crosslink

📖

neuroimaging-biomarkers

active

wiki page Created: 2026-04-02T07:20:14 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aaic-2026-neuroimaging-bioma

📖 Wiki Page

general862 wordssynced 2026-04-02

Neuroimaging and Biomarker Advances at AAIC 2026

AAIC 2026 showcased remarkable advances in neuroimaging and biomarker technologies for Alzheimer's disease (AD) diagnosis, staging, and treatment monitoring. These developments represent a paradigm shift toward minimally invasive, highly specific diagnostic tools that will transform clinical practice.

Executive Summary

flowchart TD events_aaic_2026_neuroimaging_["neuroimaging-biomarkers"] events_aaic_2026_neuroimaging_["Biomarker"] events_aaic_2026_neuroimaging_ -->|"related to"| events_aaic_2026_neuroimaging_ style events_aaic_2026_neuroimaging_ fill:#81c784,stroke:#333,color:#000 events_aaic_2026_neuroimaging_["Advances"] events_aaic_2026_neuroimaging_ -->|"related to"| events_aaic_2026_neuroimaging_ style events_aaic_2026_neuroimaging_ fill:#81c784,stroke:#333,color:#000 events_aaic_2026_neuroimaging_["showcased"] events_aaic_2026_neuroimaging_ -->|"related to"| events_aaic_2026_neuroimaging_ style events_aaic_2026_neuroimaging_ fill:#81c784,stroke:#333,color:#000 events_aaic_2026_neuroimaging_["remarkable"] events_aaic_2026_neuroimaging_ -->|"related to"| events_aaic_2026_neuroimaging_ style events_aaic_2026_neuroimaging_ fill:#81c784,stroke:#333,color:#000 style events_aaic_2026_neuroimaging_ fill:#4fc3f7,stroke:#333,color:#000

The conference highlighted three major thrust areas:

...

Neuroimaging and Biomarker Advances at AAIC 2026

AAIC 2026 showcased remarkable advances in neuroimaging and biomarker technologies for Alzheimer's disease (AD) diagnosis, staging, and treatment monitoring. These developments represent a paradigm shift toward minimally invasive, highly specific diagnostic tools that will transform clinical practice.

Executive Summary

Mermaid diagram (expand to render)

The conference highlighted three major thrust areas:

Next-generation PET tracers — improved tau, amyloid, and novel targets

Blood-based biomarkers — p-Tau217 leading the clinical translation

Integrated biomarker panels — AT(N) framework expansion with blood markers

PET Neuroimaging Advances

Tau PET Imaging

Second-generation tau PET tracers demonstrated improved specificity and clinical utility[@fleisher2024]:

| Advance | Clinical Impact |
|---|---|
| Reduced off-target binding | More accurate regional quantification |
| Broader disease applicability | PART and CTE imaging now feasible |
| Simplified quantification | Clinical implementation simplified |

Key tracers:

[^18F]Flortaucipir (Tauvid) — FDA-approved for tau imaging
Next-generation tracers in development

Amyloid PET Innovations

Novel amyloid PET tracers offer significant advantages[@rowe2023]:

Faster kinetics: Same-day imaging protocols
Improved signal-to-noise: Better signal clarity
Reduced non-specific binding: More accurate quantification

Standardization:

Centiloid scale adoption across studies
Harmonized SUVr methods
Longitudinal change thresholds

Novel PET Targets

Synaptic Imaging

[^11C]UCB-J SV2A PET enables visualization of synaptic density[@finnema2020]:

Direct measurement of synaptic loss in AD
Correlation with cognitive performance
Potential for treatment monitoring

Neuroinflammation

Third-generation TSPO tracers and P2X7 imaging:

Reduced inter-individual variability
Targeted microglial activation assessment
Correlation with disease progression

MRI Advances

Quantitative MRI Techniques

Advanced MRI methods for clinical implementation[@jack2023]:

| Technique | Application |
|---|---|
| QSM (Quantitative Susceptibility Mapping) | Iron deposition tracking |
| MT (Magnetization Transfer) | Myelin integrity |
| Diffusion MRI | Microstructural change detection |
| 7T MRI | Small vessel detection |

Functional MRI

Resting-state connectivity alterations in preclinical AD
Default mode network (DMN) changes as early markers
Task-based fMRI for cognitive reserve assessment

Blood-Based Biomarkers

p-Tau217: The Leading Marker

[p-Tau217](/biomarkers/p-tau-217) has emerged as the most specific blood-based biomarker for AD[@palmqvist2024]:

| Metric | Value |
|---|---|
| Sensitivity | >95% |
| Specificity | >95% |
| Amyloid PET correlation | r = 0.82-0.89 |
| MCI→AD prediction | High accuracy |

Key advances:

Ultrasensitive Simoa assays enabling laboratory-grade detection
Point-of-care lateral flow assays in development
FDA clearance pathway active

p-Tau181: Most Validated

The most extensively validated blood biomarker[@karikari2022]:

FDA-clearance pathway underway
Primary care screening feasibility demonstrated
Disease staging correlation established

p-Tau231: Early Detection

Earliest detectable tau abnormality[@ashton2022]:

Elevated in preclinical AD before p-Tau181
Sensitive to PART pathology
Anti-amyloid therapy response tracking

Supporting Biomarkers

| Marker | Utility |
|---|---|
| [NfL](/biomarkers/neurofilament-light-chain-nfl) | Neuroaxonal damage, progression |
| [GFAP](/entities/gfap) | Astrocyte activation, amyloid reactivity |
| NPTX1 | Synaptic dysfunction |

Clinical Integration

AT(N) Framework Expansion

The biomarker classification system now includes blood-based markers[@jack2023]:

AT(Blood): Blood-based amyloid, tau, neurodegeneration markers
Combined panels: All AT(N) markers from single blood draw
Multimodal integration: PET + MRI + fluid biomarker combinations

Implementation Advances

Reference materials for assay harmonization
International cut-point consensus
Quality control protocols
Point-of-care testing development

Clinical Trial Applications

Enrollment Optimization

Blood biomarkers enabling efficient trial recruitment:

Reduced screening failure rates
Cost-effective population screening
Diverse population access

Treatment Monitoring

Biomarker endpoints in clinical trials:

Amyloid clearance rates (PET)
Tau spreading inhibition
Atrophy modification (MRI)
Neurodegeneration markers (blood)

Summary of Key Advances

| Category | Breakthrough |
|---|---|
| Tau PET | Second-generation tracers with improved specificity |
| Amyloid PET | Same-day imaging protocols |
| Synaptic PET | SV2A imaging now possible |
| p-Tau217 | Near-clinical diagnostic accuracy |
| p-Tau231 | Earliest detectable marker |
| AT(N) Framework | Blood-based integration |
| Point-of-Care | Lateral flow assays in development |

[AAIC 2026: Imaging Advances](/events/aaic-2026/imaging-advances) — Detailed PET and MRI coverage
[AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers) — Comprehensive fluid biomarker review
[AAIC 2026: Early Detection and Preclinical AD](/events/aaic-2026/early-detection) — Preclinical detection strategies
[AAIC 2026: Biomarker Integration](/events/aaic-2026/biomarker-integration) — Multimodal approaches
[AAIC 2026: Clinical Trials Update](/events/aaic-2026/clinical-trials-update) — Trial applications

[Alzheimer's Disease Biomarkers](/research/biomarkers-alzheimers)
[Tau PET Imaging](/imaging/tau-pet)
[Amyloid PET Imaging](/imaging/amyloid-pet)
[p-Tau217](/biomarkers/p-tau-217)
[p-Tau181](/biomarkers/p-tau-181)
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
[GFAP](/entities/gfap)

References

[AAIC 2026 Conference Proceedings (2026)](https://aaic.alz.org)

[Fleisher AS, et al, Tau PET imaging: optimizing detection and quantification (2024)](https://pubmed.ncbi.nlm.nih.gov/38942015/)

[Rowe CC, et al, Amyloid PET imaging: new tracers and clinical applications (2023)](https://pubmed.ncbi.nlm.nih.gov/36738452/)

[Palmqvist S, et al, Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38597015/)

[Karikari TK, et al, Blood phospho-tau181 as a biomarker for Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35292921/)

[Ashton NJ, et al, p-Tau231 as an early marker of Alzheimer's disease pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35130406/)

[Jack CR Jr, et al, MRI-based Alzheimer's disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37940918/)

[Finnema SJ, et al, Imaging synaptic density in Alzheimer's disease with SV2A PET (2020)](https://pubmed.ncbi.nlm.nih.gov/32428579/)

📖 View canonical wiki page →

Related Entities

events-aaic-2026-neuroimaging-biomarkers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aaic-2026-neuroimaging-biomarkers
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-039c3baf0bdf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aaic-2026-neuroimaging-biomarkers'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

neuroimaging-biomarkers

Neuroimaging and Biomarker Advances at AAIC 2026

Executive Summary

Neuroimaging and Biomarker Advances at AAIC 2026

Executive Summary

PET Neuroimaging Advances

Tau PET Imaging

Amyloid PET Innovations

Novel PET Targets

Synaptic Imaging

Neuroinflammation

MRI Advances

Quantitative MRI Techniques

Functional MRI

Blood-Based Biomarkers

p-Tau217: The Leading Marker

p-Tau181: Most Validated

p-Tau231: Early Detection

Supporting Biomarkers

Clinical Integration

AT(N) Framework Expansion

Implementation Advances

Clinical Trial Applications

Enrollment Optimization

Treatment Monitoring

Summary of Key Advances

See Also

References

💬 Discussion

📗 Cite This Artifact

neuroimaging-biomarkers

Neuroimaging and Biomarker Advances at AAIC 2026

Executive Summary

Neuroimaging and Biomarker Advances at AAIC 2026

Executive Summary

PET Neuroimaging Advances

Tau PET Imaging

Amyloid PET Innovations

Novel PET Targets

Synaptic Imaging

Neuroinflammation

MRI Advances

Quantitative MRI Techniques

Functional MRI

Blood-Based Biomarkers

p-Tau217: The Leading Marker

p-Tau181: Most Validated

p-Tau231: Early Detection

Supporting Biomarkers

Clinical Integration

AT(N) Framework Expansion

Implementation Advances

Clinical Trial Applications

Enrollment Optimization

Treatment Monitoring

Summary of Key Advances

Related AAIC 2026 Content

Related NeuroWiki Content

See Also

References

💬 Discussion